HSBC Holdings’s Sarepta Therapeutics SRPT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$1.22M Buy
55,549
+22,001
+66% +$426K ﹤0.01% 1762
2025
Q4
$727K Sell
33,548
-12,041
-26% -$254K ﹤0.01% 2114
2025
Q3
$839K Sell
45,589
-35,089
-43% -$626K ﹤0.01% 1873
2025
Q2
$1.39M Sell
80,678
-23,022
-22% -$982K ﹤0.01% 1639
2025
Q1
$6.62M Sell
103,700
-76,853
-43% -$8.09M ﹤0.01% 1025
2024
Q4
$21.9M Buy
180,553
+21,914
+14% +$2.69M 0.01% 708
2024
Q3
$19.9M Buy
158,639
+156,281
+6,628% +$21.6M 0.01% 723
2024
Q2
$372K Sell
2,358
-47,489
-95% -$6.1M ﹤0.01% 2154
2024
Q1
$6.45M Buy
49,847
+21,334
+75% +$2.61M ﹤0.01% 1013
2023
Q4
$2.75M Buy
28,513
+25,998
+1,034% +$2.49M ﹤0.01% 1363
2023
Q3
$305K Buy
2,515
+519
+26% +$58.7K ﹤0.01% 2210
2023
Q2
$228K Sell
1,996
-16,780
-89% -$2.16M ﹤0.01% 2268
2023
Q1
$2.61M Buy
18,776
+4,341
+30% +$563K ﹤0.01% 1405
2022
Q4
$1.84M Buy
+14,435
New +$1.67M ﹤0.01% 1718
2022
Q3
Sell
-74,576
Closed -$5.7M 3244
2022
Q2
$5.7M Buy
74,576
+70,140
+1,581% +$5.16M 0.01% 1144
2022
Q1
$351K Sell
4,436
-450
-9% -$34.5K ﹤0.01% 2655
2021
Q4
$443K Buy
+4,886
New +$418K ﹤0.01% 2537
2021
Q3
Sell
-6,105
Closed -$479K 3158
2021
Q2
$479K Sell
6,105
-15,660
-72% -$1.19M ﹤0.01% 2211
2021
Q1
$1.62M Buy
21,765
+8,754
+67% +$808K ﹤0.01% 1379
2020
Q4
$2.22M Buy
13,011
+2,301
+21% +$341K ﹤0.01% 1296
2020
Q3
$1.52M Buy
10,710
+8,387
+361% +$1.27M ﹤0.01% 1371
2020
Q2
$372K Sell
2,323
-4,243
-65% -$577K ﹤0.01% 2017
2020
Q1
$643K Buy
+6,566
New +$751K ﹤0.01% 1659
2019
Q3
Sell
-3,572
Closed -$543K 3145
2019
Q2
$543K Sell
3,572
-734
-17% -$89.2K ﹤0.01% 2023
2019
Q1
$513K Buy
+4,306
New +$554K ﹤0.01% 2083
2018
Q2
Sell
-3,110
Closed -$230K 2690
2018
Q1
$230K Sell
3,110
-554
-15% -$36.9K ﹤0.01% 2335
2017
Q4
$203K Buy
+3,664
New +$194K ﹤0.01% 1924
2017
Q1
Sell
-8,750
Closed -$240K 2541
2016
Q4
$240K Buy
+8,750
New +$351K ﹤0.01% 2408

Other funds holding SRPT

HSBC Holdings's SRPT Position: Q1 2026 in Review

HSBC Holdings increased its Sarepta Therapeutics (SRPT) stake by 66% in Q1 2026, buying an estimated $426K and bringing the position to 55,549 shares worth $1.22M. The position accounts for ﹤0.01% of the portfolio, ranked #1762.

HSBC Holdings first reported a position in SRPT in Q4 2016 and has held it in 28 quarters since. The position peaked at $21.9M in Q4 2024. 340 funds tracked by Wall St. Rank hold SRPT as of Q1 2026.

  • HSBC Holdings held 55,549 shares of Sarepta Therapeutics worth $1.22M as of Q1 2026.
  • HSBC Holdings bought 22,001 Sarepta Therapeutics shares in Q1 2026, an estimated $426K.
  • Sarepta Therapeutics made up ﹤0.01% of HSBC Holdings's portfolio in Q1 2026, its #1762 holding.
  • HSBC Holdings first reported a position in Sarepta Therapeutics in Q4 2016 and has held it in 28 quarters since.
  • HSBC Holdings's Sarepta Therapeutics position peaked at $21.9M in Q4 2024.
  • 340 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q1 2026.

Based on HSBC Holdings's 13F filing for Q1 2026, filed 30 Apr 2026.